Hybridon公司的研究者首次报告了能口服的第二代反义寡核着酸药物，而到目前为止，人们普遍认为设计结合于DNA或RNA的反义寡核音酸，因其在胃肠道不稳定或吸收不佳而不适于口服。Hybridon公司和伯明翰阿拉巴马大学的研究者设计了含修饰的RNA和DNA片段的杂会第二代硫代磷酸寡校 Hybridon researchers first reported oral antisera to the second generation of antisense oligonucleotides, and so far it has been widely accepted that antisense oligonucleotides that bind to DNA or RNA are designed to function in the gastrointestinal tract Unstable or poorly absorbed and not suitable for oral administration. Researchers at Hybridon and the University of Alabama at Birmingham have designed a hybrid second generation phosphorothioate oligo containing modified RNA and DNA fragments